– Collaboration with Xontogeny provides funding and key advisory support for early development – PHILADELPHIA, Pa, April 11, 2022 – PolyCore Therapeutics, Inc., a biopharmaceutical… Read More
PHILADELPHIA, Pa, May 17, 2021 – PolyCore Therapeutics LLC, a biopharmaceutical company developing treatments for patients suffering from dyskinesia and cognitive impairment associated with neurodegenerative… Read More
PHILADELPHIA, Pa, February 22, 2021 – PolyCore Therapeutics LLC, a biopharmaceutical company developing treatments for patients suffering from dyskinesia and cognitive impairment associated with neurodegenerative… Read More
PHILADELPHIA, Pa, August 20, 2020 — PolyCore Therapeutics LLC, a biopharmaceutical company developing treatments for patients suffering from dyskinesia and cognitive impairment associated with neurodegenerative… Read More
PHILADELPHIA, Pa, July 20, 2020 — PolyCore Therapeutics LLC, a biopharmaceutical company developing treatments for patients suffering from dyskinesia and cognitive impairment associated with neurodegenerative… Read More